ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have been given a consensus recommendation of “Moderate Buy” by the eight analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $7.50.

Several analysts have issued reports on PRQR shares. Weiss Ratings upgraded shares of ProQR Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. Bank of America started coverage on ProQR Therapeutics in a report on Thursday, August 20th. They issued a “buy” rating and a $8.00 price objective on the stock. HC Wainwright reissued a “buy” rating on shares of ProQR Therapeutics in a research note on Monday, August 17th. JonesTrading dropped their target price on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday, June 26th. Finally, Chardan Capital dropped their target price on ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday, June 26th.

Insider Buying and Selling

In other news, CEO Daniel de Boer bought 150,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The shares were bought at an average cost of $1.74 per share, with a total value of $261,000.00. Following the completion of the purchase, the chief executive officer directly owned 300,000 shares in the company, valued at $522,000. This represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, Director Bart Filius purchased 150,000 shares of the stock in a transaction that occurred on Friday, July 17th. The shares were purchased at an average price of $1.72 per share, with a total value of $258,000.00. Following the completion of the acquisition, the director directly owned 300,000 shares in the company, valued at $516,000. The trade was a 100.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have bought 450,000 shares of company stock valued at $757,500. Insiders own 8.40% of the company’s stock.

Institutional Investors Weigh In On ProQR Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE raised its position in ProQR Therapeutics by 6.4% during the 1st quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock valued at $300,000 after purchasing an additional 11,186 shares during the last quarter. Walleye Capital LLC lifted its holdings in ProQR Therapeutics by 2.7% in the 1st quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company’s stock worth $984,000 after buying an additional 15,744 shares during the period. Axiom Investment Management LLC bought a new stake in shares of ProQR Therapeutics in the 1st quarter worth approximately $53,000. Finally, RFG Advisory LLC grew its position in shares of ProQR Therapeutics by 236.8% in the 2nd quarter. RFG Advisory LLC now owns 64,000 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 45,000 shares during the last quarter. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Stock Performance

Shares of PRQR opened at $1.65 on Wednesday. ProQR Therapeutics has a fifty-two week low of $1.33 and a fifty-two week high of $3.10. The firm has a market cap of $173.84 million, a price-to-earnings ratio of -3.59 and a beta of 0.06. The firm has a 50 day moving average price of $1.95 and a 200-day moving average price of $1.76.

ProQR Therapeutics (NASDAQ:PRQR) last released its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.04. The company had revenue of $10.00 million for the quarter, compared to analyst estimates of $4.56 million. ProQR Therapeutics had a negative net margin of 223.51% and a negative return on equity of 73.83%. As a group, equities research analysts predict that ProQR Therapeutics will post -0.45 earnings per share for the current year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. (NASDAQ: PRQR) is a biotechnology company focused on developing RNA-based medicines for genetic and other serious diseases. The company’s research platform is designed to modify RNA and potentially correct disease-causing genetic defects without permanently changing a patient’s DNA.

ProQR has primarily pursued treatments for inherited retinal disorders and other conditions affecting the eye. Its pipeline has included investigational RNA therapies such as sepofarsen, developed for Leber congenital amaurosis type 10, and ultevursen, developed for Usher syndrome type 2A.